<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02229747</url>
  </required_header>
  <id_info>
    <org_study_id>107.250</org_study_id>
    <nct_id>NCT02229747</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Meloxicam Suspension Versus Diclofenac Suspension or Nimesulide Suspension in Patients With a Diagnosis of Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis</brief_title>
  <official_title>Randomized, Open-label, Controlled Trial to Assess the Clinical Efficacy and Safety of Meloxicam Suspension 0.25 mg/kg/Day Once a Day, Versus Diclofenac 1 mg/kg/Day Twice a Day or Nimesulide 4 mg/kg/Day Twice a Day, for Five Days in the Treatment of Patients With Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study was to assess the clinical efficacy and safety of meloxicam
      suspension 0.25 mg/kg/day once a day, versus diclofenac suspension 1 mg/kg/day twice a day or
      nimesulide suspension 4 mg/kg/day twice a day, after five days of treatment in patients with
      a diagnosis of acute, non-bacterial pharyngitis, pharyngotonsillitis or laryngitis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <primary_completion_date type="Actual">February 2002</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in spontaneous pharyngeal pain</measure>
    <time_frame>baseline, 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pharyngeal pain on deglutition (dysphagia)</measure>
    <time_frame>baseline, 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pharyngeal hyperemia</measure>
    <time_frame>baseline, 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in systemic manifestations (fever, adenomegaly and general malaise)</measure>
    <time_frame>baseline, 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>baseline, 5 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Pharyngitis</condition>
  <arm_group>
    <arm_group_label>Meloxicam suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenac suspension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Nimesulide suspension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam</intervention_name>
    <arm_group_label>Meloxicam suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
    <arm_group_label>Diclofenac suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nimesulide</intervention_name>
    <arm_group_label>Nimesulide suspension</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both genders between 2 and 8 years old

          -  Outpatients, with onset of symptoms not more than 72 hours prior to presentation,
             patients with acute non-bacterial pharyngitis or pharyngotonsillitis diagnosed
             according to the following criteria:

               -  Spontaneous pharyngeal pain, pharyngeal pain upon swallowing, pharyngeal and/or
                  tonsillar hyperemia, absence of purulent plaques, pharyngeal smear negative for
                  ß-hemolytic Streptococcus or Strepto Test® and Treatment with an Non-steroidal
                  anti-inflammatory drugs (NSAID) required or recommended

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to study medications or NSAID's

          -  Pharyngeal smear positive for ß-hemolytic Streptococcus

          -  treatment with antimicrobials prior to enrolment in the study

          -  Chronic infection, infectious mononucleosis, peptic ulcer disease that has been active
             in the previous 6 months

          -  Asthma

          -  nasal polyps

          -  angioneurotic edema or urticaria after the administration of aspirin or NSAID's

          -  Concomitant treatment with anticoagulants (including heparin), lithium or methotrexate

          -  Concomitant administration of other NSAID's (including high dose aspirin) or
             analgesics, except authorized rescue drugs

          -  Administration of any NSAID during the three previous days or of analgesics within six
             hours prior to the administration of the first study drug dose

          -  Treatment with corticosteroids at the time of enrollment or within the two previous
             months

          -  Known liver, renal or hematological disease

          -  Participation in another clinical trial during the study period or during the previous
             month

          -  Previous enrollment in this study

          -  Inability to comply with the protocol

          -  Suspected acute bacterial pharyngitis or pharyngotonsillitis (under the following
             clinical criteria):

               -  Clinical presentation characterized by a rapid onset, very high fever (&gt;38.5°C),
                  severe pharyngeal pain, cervical adenopathy, intense headache, purulent
                  pharyngeal plaques, evidence of peritonsillar abscess or phlegmon
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2014</study_first_submitted>
  <study_first_submitted_qc>August 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2014</study_first_posted>
  <last_update_submitted>August 29, 2014</last_update_submitted>
  <last_update_submitted_qc>August 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharyngitis</mesh_term>
    <mesh_term>Laryngitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Meloxicam</mesh_term>
    <mesh_term>Nimesulide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

